Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
20000
¥ million (increase in full-year revenue forecast)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedIFRSNet Sales350,377¥ millionYear on year +64.5%Progress 48.7%
Operating profit115,244¥ millionYear on year +55.8%Progress 50.1%
Ordinary income107,257¥ millionYear on year +9.9%Progress 48.6%
Net income attributable to owners of the parent119,546¥ millionYear on year +44.0%Progress 56.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥140.47
Financial position at period-end
Total assets2,641,068¥ million
of which net assets 1,746,978 ¥ millionEquity ratio 66.1%vs. prior year-end +0.8pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+142,166
Investment-434,663
Financials-35,431
Net change-327,928
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥376,482 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥720,000 million (YoY +44.1%)
Operating profit¥230,000 million (YoY +35.1%)
Ordinary income¥220,500 million (YoY -9.1%)
Net income¥212,500 million (YoY +1.6%)
Revision to Earnings ForecastNet Sales ¥700,000 million → ¥720,000 million（+2.9%） / Operating profit ¥220,000 million → ¥230,000 million（+4.5%） / Ordinary income ¥220,000 million → ¥220,500 million（+0.2%） / Net income ¥210,000 million → ¥212,500 million（+1.2%）
Annual Dividend Forecast¥76 per share → ¥86 per share（+13.2%）
Shareholder Return PolicyStable dividends with DOE of 4% or more as a guideline
Factors Behind Changes in Business Performance
The acquisition and consolidation of businesses including the edaravone business, the JT pharmaceutical business and Torii Pharmaceutical, expanded sales of RADICAVA and cefiderocol, growth in domestic products, and increases in royalty income and share of profit of investments accounted for using the equity method due to strong performance in ViiV's HIV business. On the cost side, amortization of intangible assets, US business expenses and impairment losses increased.
Disclosure regarding the going concern assumption
No applicable matters (the note on the going concern assumption states that there are no applicable matters)
Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 Yes (retrospective adjustment of prior-period figures accompanying the finalization of provisional accounting treatment for business combinations)
Changes in the scope of consolidationMaterial changes None / New 2 companies (RADIANCE NEWCO, LLC and 1 other company. RADIANCE NEWCO, LLC was absorbed through a merger effective 1 July 2026.) / Excluded Not disclosed
Material subsequent eventsComprehensive resolution concerning the execution of an acquisition agreement for US-based IntraBio and the issuance of domestic unsecured straight bonds. IntraBio is scheduled to become a wholly owned subsidiary, and the bonds are scheduled to be issued in an aggregate amount of no more than ¥100 billion.
Impairment loss¥5,082 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on recognition of negative goodwill ¥48,970 million / Extraordinary loss Impairment Losses ¥5,082 million / Notes Under IFRS, both are recorded primarily in other income and other expenses.
Depreciation and amortization¥41,861 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for analysts)
Issued Shares at Period-End889,632,195 shares
Treasury Shares at Period-End38,458,657 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥350,377 million (YoY +64.5%) |
| Operating profit | ¥115,244 million (YoY +55.8%) |
| Ordinary income | ¥107,257 million (YoY +9.9%) |
| Profit attributable to owners of the parent | ¥119,546 million (YoY +44.0%) |
| Net income per share | ¥140.47 |
| Equity ratio | End of the current fiscal period 66.1% / End of previous period 65.3% |
| Total assets | ¥2,641,068 million |
| Net assets | ¥1,746,978 million |
| Cash flows from operating activities | ¥142,166 million |
| Cash flows from investing activities | ¥-434,663 million |
| Cash flows from financing activities | ¥-35,431 million |
| Cash and cash equivalents at end of period | ¥376,482 million |
| Full-year earnings forecast | Net Sales ¥720,000 million (YoY +44.1%) / Operating profit ¥230,000 million (YoY +35.1%) / Ordinary income ¥220,500 million (YoY -9.1%) / Net income ¥212,500 million (YoY +1.6%) |
| Revision to Earnings Forecast | Net Sales ¥700,000 million → ¥720,000 million（+2.9%） / Operating profit ¥220,000 million → ¥230,000 million（+4.5%） / Ordinary income ¥220,000 million → ¥220,500 million（+0.2%） / Net income ¥210,000 million → ¥212,500 million（+1.2%） |
| Annual Dividend Forecast | ¥76 per share → ¥86 per share（+13.2%） |
| Shareholder Return Policy | Stable dividends with DOE of 4% or more as a guideline |
| Depreciation and amortization | ¥41,861 million |
| Impairment loss | ¥5,082 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on recognition of negative goodwill ¥48,970 million / Extraordinary loss Impairment Losses ¥5,082 million / Notes Under IFRS, both are recorded primarily in other income and other expenses. |
| Disclosure regarding the going concern assumption | No applicable matters (the note on the going concern assumption states that there are no applicable matters) |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement Yes (retrospective adjustment of prior-period figures accompanying the finalization of provisional accounting treatment for business combinations) |
| Changes in the scope of consolidation | Material changes None / New 2 companies (RADIANCE NEWCO, LLC and 1 other company. RADIANCE NEWCO, LLC was absorbed through a merger effective 1 July 2026.) / Excluded Not disclosed |
| Material subsequent events | Comprehensive resolution concerning the execution of an acquisition agreement for US-based IntraBio and the issuance of domestic unsecured straight bonds. IntraBio is scheduled to become a wholly owned subsidiary, and the bonds are scheduled to be issued in an aggregate amount of no more than ¥100 billion. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts) |
| Issued Shares at Period-End | 889,632,195 shares |
| Treasury Shares at Period-End | 38,458,657 shares |
| Factors Behind Changes in Business Performance | The acquisition and consolidation of businesses including the edaravone business, the JT pharmaceutical business and Torii Pharmaceutical, expanded sales of RADICAVA and cefiderocol, growth in domestic products, and increases in royalty income and share of profit of investments accounted for using the equity method due to strong performance in ViiV's HIV business. On the cost side, amortization of intangible assets, US business expenses and impairment losses increased. |
Items this document does not state (6)
Operating MarginPayout ratioSegment revenueSegment profitRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The reasons given were that the results of growth investments made in fiscal 2025 were reflected in performance, expanded sales of RADICAVA and cefiderocol, growth in domestic products, and increases in royalty income and share of profit of investments accounted for using the equity method due to strong performance at ViiV.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.